News & Updates

Treatment with benralizumab allows tapering of inhaled corticosteroid (ICS) doses for patients with severe eosinophilic asthma, without compromising disease control and increasing exacerbations, as shown in the results of the phase IV SHAMAL study.

Treatment with cefoperazone-sulbactam demonstrates similar efficacy to that of piperacillin-tazobactam in adult patients with severe community-acquired pneumonia (SCAP), according to a study. However, after adjusting for disease severity, cefoperazone-sulbactam appears superior to piperacillin-tazobactam.

Local intranasal treatment with budesonide does not appear to be effective for persistent hyposmia in patients with nonsevere COVID-19, according to a study.

A cross-sectional analysis has found an association between insomnia, poor sleep quality, and extremes of sleep duration and increased COVID-19 infection and hospitalization.

In the treatment of patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, and locally advanced nonsmall cell lung cancer (NSCLC), the use of durvalumab immunotherapy in combination with curative radiotherapy yields survival gains with tolerable adverse events (AEs), as shown in the results of the phase II DOLPHIN trial.